Literature DB >> 18084917

Virtual screening for the discovery of bioactive natural products.

Judith M Rollinger1, Hermann Stuppner, Thierry Langer.   

Abstract

In this survey the impact of the virtual screening concept is discussed in the field of drug discovery from nature. Confronted by a steadily increasing number of secondary metabolites and a growing number of molecular targets relevant in the therapy of human disorders, the huge amount of information needs to be handled. Virtual screening filtering experiments already showed great promise for dealing with large libraries of potential bioactive molecules. It can be utilized for browsing databases for molecules fitting either an established pharmacophore model or a three dimensional (3D) structure of a macromolecular target. However, for the discovery of natural lead candidates the application of this in silico tool has so far almost been neglected. There are several reasons for that. One concerns the scarce availability of natural product (NP) 3D databases in contrast to synthetic libraries; another reason is the problematic compatibility of NPs with modern robotized high throughput screening (HTS) technologies. Further arguments deal with the incalculable availability of pure natural compounds and their often too complex chemistry. Thus research in this field is time-consuming, highly complex, expensive and ineffective. Nevertheless, naturally derived compounds are among the most favorable source of drug candidates. A more rational and economic search for new lead structures from nature must therefore be a priority in order to overcome these problems. Here we demonstrate some basic principles, requirements and limitations of virtual screening strategies and support their applicability in NP research with already performed studies. A sensible exploitation of the molecular diversity of secondary metabolites however asks for virtual screening concepts that are interfaced with well-established strategies from classical pharmacognosy that are used in an effort to maximize their efficacy in drug discovery. Such integrated virtual screening workflows are outlined here and shall help to motivate NP researchers to dare a step towards this powerful in silico tool.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18084917      PMCID: PMC7124045          DOI: 10.1007/978-3-7643-8117-2_6

Source DB:  PubMed          Journal:  Prog Drug Res        ISSN: 0071-786X


  78 in total

1.  Detailed analysis of scoring functions for virtual screening.

Authors:  M Stahl; M Rarey
Journal:  J Med Chem       Date:  2001-03-29       Impact factor: 7.446

Review 2.  Stategic trends in the drug industry.

Authors:  Jürgen Drews
Journal:  Drug Discov Today       Date:  2003-05-01       Impact factor: 7.851

3.  Structure-based discovery of potassium channel blockers from natural products: virtual screening and electrophysiological assay testing.

Authors:  Hong Liu; Yang Li; Mingke Song; Xiaojian Tan; Feng Cheng; Suxin Zheng; Jianhua Shen; Xiaomin Luo; Ruyun Ji; Jianmin Yue; Guoyuan Hu; Hualiang Jiang; Kaixian Chen
Journal:  Chem Biol       Date:  2003-11

4.  Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry.

Authors:  Miklos Feher; Jonathan M Schmidt
Journal:  J Chem Inf Comput Sci       Date:  2003 Jan-Feb

5.  Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database.

Authors:  Zaneta Nikolovska-Coleska; Liang Xu; Zengjian Hu; York Tomita; Peng Li; Peter P Roller; Renxiao Wang; Xueliang Fang; Ribo Guo; Manchao Zhang; Marc E Lippman; Dajun Yang; Shaomeng Wang
Journal:  J Med Chem       Date:  2004-05-06       Impact factor: 7.446

6.  Recovering the true targets of specific ligands by virtual screening of the protein data bank.

Authors:  Nicodéme Paul; Esther Kellenberger; Guillaume Bret; Pascal Müller; Didier Rognan
Journal:  Proteins       Date:  2004-03-01

7.  Parallel screening: a novel concept in pharmacophore modeling and virtual screening.

Authors:  Theodora M Steindl; Daniela Schuster; Christian Laggner; Thierry Langer
Journal:  J Chem Inf Model       Date:  2006 Sep-Oct       Impact factor: 4.956

8.  Pharmacophore identification, in silico screening, and virtual library design for inhibitors of the human factor Xa.

Authors:  Eva M Krovat; Karin H Frühwirth; Thierry Langer
Journal:  J Chem Inf Model       Date:  2005 Jan-Feb       Impact factor: 4.956

9.  Acetylcholinesterase inhibitory activity of scopolin and scopoletin discovered by virtual screening of natural products.

Authors:  Judith M Rollinger; Ariane Hornick; Thierry Langer; Hermann Stuppner; Helmut Prast
Journal:  J Med Chem       Date:  2004-12-02       Impact factor: 7.446

10.  Pharmacophore modeling and in silico screening for new P450 19 (aromatase) inhibitors.

Authors:  Daniela Schuster; Christian Laggner; Theodora M Steindl; Anja Palusczak; Rolf W Hartmann; Thierry Langer
Journal:  J Chem Inf Model       Date:  2006 May-Jun       Impact factor: 4.956

View more
  27 in total

Review 1.  Virtual screening: an endless staircase?

Authors:  Gisbert Schneider
Journal:  Nat Rev Drug Discov       Date:  2010-04       Impact factor: 84.694

2.  An in silico protocol for identifying mTOR inhibitors from natural products.

Authors:  Lei Chen; Ling Wang; Qiong Gu; Jun Xu
Journal:  Mol Divers       Date:  2014-08-26       Impact factor: 2.943

3.  Protein-ligand interaction studies of retinol-binding protein 3 with herbal molecules using AutoDock for the management of Eales' disease.

Authors:  Anshul Tiwari; Sandeep Saxena; A B Pant; Prachi Srivastava
Journal:  J Ocul Biol Dis Infor       Date:  2012-12-30

Review 4.  Counting on natural products for drug design.

Authors:  Tiago Rodrigues; Daniel Reker; Petra Schneider; Gisbert Schneider
Journal:  Nat Chem       Date:  2016-04-25       Impact factor: 24.427

5.  Design and optimization of SPR-based binding assay for evaluation and screening of MITF-E-box binding inhibitor.

Authors:  V K Morya; Manki Son; Hyang-Bok Lee; Eun-ki Eun-ki
Journal:  Mol Biotechnol       Date:  2014-03       Impact factor: 2.695

6.  Quinazoline clubbed 1,3,5-triazine derivatives as VEGFR2 kinase inhibitors: design, synthesis, docking, in vitro cytotoxicity and in ovo antiangiogenic activity.

Authors:  Prateek Pathak; Parjanya Kumar Shukla; Vikas Kumar; Ankit Kumar; Amita Verma
Journal:  Inflammopharmacology       Date:  2018-04-16       Impact factor: 4.473

7.  Fast and automated functional classification with MED-SuMo: an application on purine-binding proteins.

Authors:  Olivia Doppelt-Azeroual; François Delfaud; Fabrice Moriaud; Alexandre G de Brevern
Journal:  Protein Sci       Date:  2010-04       Impact factor: 6.725

8.  Virtual Screening of Phytochemicals to Novel Target (HAT) Rtt109 in Pneumocystis Jirovecii using Bioinformatics Tools.

Authors:  Ramya Sugumar; Abhinand Ponneri Adithavarman; Anusha Dakshinamoorthi; Darling Chellathai David; Padmavathi Kannan Ragunath
Journal:  J Clin Diagn Res       Date:  2016-03-01

Review 9.  Discovery and resupply of pharmacologically active plant-derived natural products: A review.

Authors:  Atanas G Atanasov; Birgit Waltenberger; Eva-Maria Pferschy-Wenzig; Thomas Linder; Christoph Wawrosch; Pavel Uhrin; Veronika Temml; Limei Wang; Stefan Schwaiger; Elke H Heiss; Judith M Rollinger; Daniela Schuster; Johannes M Breuss; Valery Bochkov; Marko D Mihovilovic; Brigitte Kopp; Rudolf Bauer; Verena M Dirsch; Hermann Stuppner
Journal:  Biotechnol Adv       Date:  2015-08-15       Impact factor: 14.227

10.  Mapping the intellectual structure of the coronavirus field (2000-2020): a co-word analysis.

Authors:  Aliakbar Pourhatami; Mohammad Kaviyani-Charati; Bahareh Kargar; Hamed Baziyad; Maryam Kargar; Carlos Olmeda-Gómez
Journal:  Scientometrics       Date:  2021-06-15       Impact factor: 3.238

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.